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Abstract 
Introduction. Heart transplant (HTx) recipients need to follow a complex therapeutic regimen. We assessed the 
international prevalence and variability in nonadherence to six nonpharmacologic treatment components (physical 
activity, sun protection, diet, alcohol use, nonsmoking, and outpatient follow‐up visits).  
Methods. We used self‐report data of 1397 adult HTx recipients from the 36‐HTx‐center, 11‐country, 4‐continent, 
cross‐sectional BRIGHT study (ClinicalTrials.gov ID: NCT01608477). The nonadherence definitions used were as 
follows: Physical activity: <3 times/wk 20 minutes’ vigorous activity, <5 times/wk 30 minutes’ moderate activity, or 
<5 times/wk a combination of either intensity; Sun protection: not “always” applying any sun protection; Diet: not 
“often” or “always” following recommended diet(s); Alcohol use: >1 alcoholic drink/d (women) or >2 drinks/d 
(men); Smoking: current smokers or stopped <1 year before; Follow‐up visits: missing ≥1 of the last 5 outpatient 
follow‐up visits. Overall prevalence figures were adjusted to avoid over‐ or underrepresentation of countries. 
Between‐country variability was assessed within each treatment component via chi‐square testing.  
Results. The adjusted study‐wide nonadherence prevalence figures were as follows: 47.8% for physical activity (95% 
CI [45.2‐50.5]), 39.9% for sun protection (95% CI [37.3‐42.5]), 38.2% for diet recommendations (95% CI [35.1‐
41.3]), 22.9% for alcohol consumption (95% CI [20.8‐25.1]), 7.4% for smoking cessation (95% CI [6.1‐8.7]), and 
5.7% for follow‐up visits (95% CI [4.6‐6.9]). Significant variability was observed between countries in all treatment 
components except follow‐up visits.  
Conclusion. Nonadherence to the post‐HTx nonpharmacologic treatment regimen is prevalent and shows significant 
variability internationally, suggesting a need for tailored adherence‐enhancing interventions.  
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1 INTRODUCTION 
Evidence shows that long‐term graft attrition rates after adult heart transplantation (HTx) have not 
changed markedly over time and that reduced mortality rates are almost exclusively attributable to 
survival gains in the early post‐HTx phase.1,2 Improving long‐term survival is therefore a priority in 
research and clinical practice. Nevertheless, immunosuppressant intake might hamper long‐term 
survival.
3
 Indeed, long‐term immunosuppressant intake may trigger systemic and metabolic 
complications and elevate the risk of cancer, augmenting the risk of graft injury and all‐cause mortality. 
According to the most recent registry data,
4
 at 5 years post‐HTx, 51.1% of HTx recipients have renal 
dysfunction, 35.5% have diabetes, 29.3% have cardiac allograft vasculopathy, and 15.9% have 
malignancy (all types combined).  
 
To prevent or delay the incidence of these comorbidities, post‐HTx care guidelines5 recommend 
lifelong follow‐up to monitor graft function and lifestyle modifications including weight control, physical 
activity, diet (eg, low fat and sodium intake), abstinence from smoking or heavy alcohol intake, and use 
of sun protection. It remains unclear, however, to what extent HTx recipients are able to follow this 
complex therapeutic regimen. The bulk of evidence on post‐HTx behavior focuses on medication 
adherence; robust evidence on the prevalence of nonadherence to the post‐HTx nonpharmacologic 
therapeutic regimen is scarce.  
 
A 2007 meta‐analysis6 showed nonadherence rates of 33.7 cases per 100 patient‐years for physical 
activity, 28.1 cases for following a diet, 8.5 cases for attending clinic appointments, 4.9 cases for alcohol 
use, and 3.2 cases for tobacco use in HTx recipients. However, these estimates were based on a small 
number of available studies. Moreover, although meta‐analyses pool and summarize evidence, 
nonadherence prevalence rates for each behavior might vary widely across studies due to methodological 
issues, for example, nonstandard measurement methods or sampling strategies. Since that 2007 meta‐
analysis, the few related studies published have most commonly used small samples or focused on a 
single behavior. Larger studies investigating multiple behaviors enrolled patients from one center only,
6, 7
 
providing no evidence on variations in HTx recipients’ health behaviors between centers or countries. 
Physical inactivity in the general population, for instance, is far more prevalent in Belgium, Spain, and 
the UK than in the Netherlands, Germany, or France,
8
 and tobacco smoking is more prevalent in Europe 
than in the Americas.
9
 Generating and comparing regional nonadherence rates could help HTx centers 
prioritize lifestyle interventions and plan resources to remedy problems specific to their local populations. 
Therefore, the international HTx community would benefit from a single large study using a 
homogeneous methodological approach to investigate the prevalence of nonadherence to all post‐HTx 
nonpharmacologic treatment components.  
 
Therefore, this study has two aims: (i) to describe the prevalence of nonadherence to the post‐HTx 
nonpharmacologic treatment regimen (ie, physical activity, sun protection, diet recommendations, 
limiting alcohol use, smoking abstinence, and appointment keeping); and (ii) to describe between‐country 
variability in nonadherence rates regarding these health behaviors and test its significance in a large 
sample of adult HTx recipients from various countries.  
  
2 PATIENTS AND METHODS 
This study used data from the Building Research Initiative Group: Chronic Illness Management and 
Adherence in Transplantation (BRIGHT) study
10,11
 (ClinicalTrials.gov ID: NCT01608477), a cross‐
sectional study assessing healthcare providers’ practice patterns and the prevalence and variability of 
nonadherence to the post‐HTx treatment regimen in 36 HTx centers from 11 countries in Asia, Europe, 
North America, and South America.  
2.1 Sampling and data collection 
The BRIGHT study used a multistage sampling approach. Countries and HTx centers were included 
via convenience sampling, enrolling at least 2 centers per country. HTx centers were eligible to 
participate in the study if they met all of the following criteria:  
 
1. Performance of at least 50 HTx over the 60 months prior to inclusion. 
2. Location in Europe, North America, South America, or Australia. 
3. Willingness to provide formal study support through the center's HTx director and responsible 
administrator.  
4.  
Using a stratified random sampling approach based on center size,
10 
HTx recipients were eligible to 
participate if they:  
 
1. Were adults (≥18 years at time of enrollment); 
2. Were transplanted and followed up for routine care at a participating HTx center; 
3. Received their HTx as a single‐organ transplant; 
4. Underwent a first‐time HTx (no retransplantation); 
5. Were 1‐5 years post‐HTx; 
6. Were able to read and understand one of the study languages; and 
7. Were willing to provide written informed consent. 
 
HTx recipients were excluded if they had participated in adherence intervention research or drug trials 
during the 6 months prior to inclusion or if they had received professional support for medication intake. 
Detailed information on the methodology of the BRIGHT study is reported elsewhere.
10,11 
 
The data were collected (once for each HTx recipient) between March 2012 and October 2015 after 
obtaining ethical approval from each participating center's institutional review board (IRB) or ethics 
committee.  
2.2 Variables and measurement 
To describe the sample, sociodemographic characteristics were collected via patient interviews during 
a scheduled clinic visit (ie, age, gender, marital status, ethnicity, educational level, and employment 
status). Clinical data (date of HTx and heart failure etiology) were captured based on chart reviews.  
 
Nonadherence to 6 components of the nonpharmacologic treatment regimen (ie, physical activity, 
nonsmoking status, limited alcohol use, use of sun protection measures, following of diet 
recommendations, and the keeping of follow‐up appointments) was assessed by a self‐report 
questionnaire during a scheduled outpatient clinic visit.
12-16
 Table 1 describes how each component was 
measured and scored.  
  
Table 1. Self‐report instruments used to measure the investigated health behaviors 
Variable 
 
Instrument 
 
 Number of items 
 Recall period 
 Response options 
 Nonadherence definitions 
 
Validity/Reliability 
 
    
Physical activity 
(PA) 
Brief Physical 
Activity Assessment 
tool (12) 
 2 items 
 Average week 
 No. times/wk 20 min of vigorous PA: <1 time/wk/1‐2 
times/wk/ ≥3 times/wk 
and 
No. times/wk 30 min of moderate PA: <1 time/wk/1‐
2 times/wk/3‐4 times/wk/ ≥5 time/wk 
 Nonadherence: <3 times/wk vigorous PA OR 
<5 times/wk moderate PA OR <5 times/wk a 
combination of either PA intensities  
Assessed against an 
accelerometer‐Criterion 
validity (10) (ĸ = 0.40, 95% 
CI = 0.12‐0.69) 
‐Inter‐rater reliability (10) 
(ĸ = 0.53, 95% CI = 0.33‐
0.72) 
Smoking status 1 item from the Swiss 
Health Survey (13) 
 1 item 
 1 y 
 Currently smoking/Stopped smoking less than a year 
before/Stopped smoking more than a year 
before/Never smoked  
 Nonadherent: currently smoking or stopped less than a 
year before 
No available information on 
psychometric properties 
Alcohol use Investigator 
developed (14) 
 3 items 
 Average week 
 Yes/No  
 No. shots or glasses/wk (1.5 oz. = 45 mL); 
 No. pints of beer/wk (1 pint = 12 oz. = 355 mL); 
 No. glasses of wine/wk (1 glass = 5 oz.  = 148 mL) 
 No. times drinking/wk: Daily/3‐4 times/wk/1‐
2 times/mo/<1 time/mo/Never 
 Nonadherent = heavy drinker: >1 drink/d (women); 
>2 drinks/d (men) 
No available information on 
psychometric properties 
Sun protection Swiss study on health 
of people with cancer, 
leukemia, and tumor 
in childhood (15) 
and 
Cambridge University 
Hospitals’ perception 
of skin cancer in 
transplant recipients 
scale (16)  
 4 items 
 Current situation 
 Using sunscreen, wearing protective clothing, staying 
in the shade, being sensitive to the time of the day: 5‐
point Likert scale ranging from “1 = never” to 
“5 = always”  
 Nonadherent: not always using at least 1 of these sun 
protection methods 
Unidimensional scale, having 
a Cronbach's alpha of 0.59 
Diet 
recommendations 
Investigator 
developed 
 5 items 
 1 y 
 Yes/No for advice to follow a specific diet (low salt, 
low calorie, low saturated fats, low sugar, or other 
diets) and, correspondingly, a 5‐point Likert scale 
ranging from “1 = never” to “5 = always” to evaluate 
adherence to each recommended diet  
 Nonadherent: score 1‐3 on any of the 5 diets 
recommended by the transplant team 
No available information on 
psychometric properties 
Follow‐up 
appointment 
keeping 
Investigator 
developed 
 1 item 
 Previous 5 scheduled clinic appointments 
 No. appointments missed: 6‐point scale ranging from 
“none” to “6 = all 5 appointments” 
 Nonadherent: missed ≥ 1 appointment 
No available information on 
psychometric properties 
    
 
a 352 HTx recipients reported not having been recommended any diet. 
  
2.3 Statistical analysis 
Frequencies and percentages (for categorical variables) or measures of central tendency and dispersion 
(for continuous variables) are used to describe the sample. The data were aggregated on the country level 
and the level of the entire sample as appropriate. The prevalence of nonadherence to each of the 
nonpharmacologic treatment components is presented as a percentage. To avoid over‐ or 
underrepresentation of any country's HTx recipient population, the overall nonadherence prevalence for 
each treatment component was calculated as a weighted average. This was accomplished by multiplying 
each country's nonadherence rate by a weighting factor that corresponds to the ratio of the HTx recipient 
population in the corresponding country to that of all included countries in the time period corresponding 
to that of the study's data collection in the country.  
 
Standard deviations and ranges are used to describe between‐country variability in nonadherence 
prevalence. Chi‐square testing was used to determine the significance of this variability. After applying 
the Bonferroni correction to the significance level of P < .05 to account for multiple testing, the 
significance level was set at 0.008.  
 
With one exception—alcohol use—missing data affected fewer than 10% of the cases involving the 
variables used to calculate nonadherence to the investigated health behaviors. Accordingly, patients with 
completely missing data on a health behavior of interest were excluded only from the corresponding 
analysis (available‐case analysis). For alcohol use, missing data in the 2 variables, that is, number of 
drinks/week and weekly drinking frequency, were imputed using the R (version 3.4.2) programming 
language and the MICE (multivariate imputation by chained equations) package. For all other analyses, 
Stata® 15 (StataCorp LLC, College Station, TX, USA) was used.  
3 RESULTS 
3.1 Sample characteristics 
At the 36 participating centers, of 2523 HTx recipients found eligible for inclusion, 1677 were 
randomly selected and invited to participate. Of this number, 244 declined and 36 died before enrollment, 
resulting in a final sample size of 1397 HTx recipients. Information on the sample size per country and 
health behavior is presented in Table 2.  
  
Table 2. Number of heart transplant recipients with data on each of the investigated behaviors (per country and per health behavior) 
 
Appointment 
keeping 
Smoking 
cessation 
Alcohol 
use 
Diet 
recommendations 
Sun 
protection 
Physical 
activity 
       
Belgium (n = 74) 74 74 74 48 70 74 
France (n = 160) 157 157 160 110 150 146 
Germany (n = 67) 65 64 67 19 62 65 
Italy (n = 111) 111 110 111 64 110 105 
Spain (n = 227) 224 221 227 218 220 222 
Switzerland (n = 47) 46 46 47 14 44 46 
United Kingdom 
(n = 99) 
99 99 98 28 98 96 
Canada (n = 121) 116 115 120 88 116 116 
USA (n = 340) 336 335 339 278 334 334 
Australia (n = 51) 51 51 51 26 51 51 
Brazil (n = 100) 97 97 100 71 94 85 
Total sample 
(N = 1397) 
1376 1369 1394 964a 1349 1340 
Missing data 21 28 3 81 48 57 
       
 
a 352 HTx recipients reported not having been recommended any diet. 
Table 3 shows the main characteristics of the final HTx recipient sample, overall, and per country. 
Participants were 72.7% (1011) male, and on average 53.7 (SD: 13.2) years old and 3.4 (SD: 1.4) years 
post‐HTx at time of enrollment. 
Table 3. Sociodemographic and clinical characteristics of the participating heart transplant recipients 
 
Overall 
N = 1397 
 
Europe n = 785 
 North America 
n = 461 
 Australia 
n = 51 
 South America 
n = 100 
 Belgium 
n = 74 
France 
n = 160 
Germany 
n = 67 
Italy 
n = 111 
Spain 
n = 227 
Switzerland 
n = 47 
UK 
n = 99 
 Canada 
n = 121 
USA 
n = 340 
 Australia 
n = 51 
 
Brazil n = 100 
                 
Age, years (n) 1380  74 160 65 111 227 47 98  113 335  51  99 
Mean (SD) 53.7 (13.2) 
 
53.3 (12.6) 50.2 (13.0) 55.3 (10.3) 
56.7 
(12.5) 
56.5 
(11.7) 
50.1 (14.6) 
49.3 
(14.8) 
 
55 (13.4) 
56.3 
(12.8) 
 
49.7 (14.2) 
 
46.8 (13.3) 
Gender (n) 1390  74 160 65 111 227 47 98  120 337  51  100 
Male, n (%) 
1011 
(72.7%) 
 
50 (67.6%) 
121 
(75.6%) 
50 (76.9%) 
93 
(83.8%) 
174 
(76.7%) 
32 (68.1%) 
76 
(77.6%) 
 
87 (72.5%) 
229 
(68%) 
 
31 (60.8%) 
 
68 (68%) 
Ethnicity (n) 1381  74 159 65 111 224 47 99  119 336  47  100 
Caucasian, n (%) 
1186 
(85.9%) 
 
73 (98.7%) 
142 
(89.3%) 
65 (100%) 
110 
(99.1%) 
205 
(91.5%) 
43 (91.5%) 
93 
(93.9%) 
 106 
(89.1%) 
251 
(74.7%) 
 
33 (70.2%) 
 
65 (65%) 
Education (n) 1377  73 158 65 111 220 47 99  119 339  50  96 
Primary school, n (%) 187 (13.6%) 
 
3 (4.1%) 10 (6.3%) 7 (10.8%) 
37 
(33.3%) 
94 
(42.7%) 
5 (10.6%) 0 
 
3 (2.4%) 3 (0.9%) 
 
0 
 
25 (26%) 
Secondary school, n 
(%) 
426 (30.9%) 
 
42 (57.5%) 53 (33.5%) 6 (9.2%) 51 (46%) 
60 
(27.3%) 
3 (6.4%) 
45 
(45.5%) 
 
35 (29.4%) 
71 
(20.9%) 
 
9 (18%) 
 
51 (53.1%) 
Further education, n 
(%) 
294 (21.4%) 
 
15 (20.6%) 64 (40.5%) 40 (61.5%) 2 (1.8%) 
25 
(11.4%) 
32 (68.1%) 24 (24.2) 
 
16 (13.5%) 
59 
(17.4%) 
 
17 (34%) 
 
0 
University, n (%) 470 (34.1%) 
 
13 (17.8%) 31 (19.6%) 12 (18.5%) 
21 
(18.9%) 
41 
(18.6%) 
7 (14.9%) 
30 
(30.3%) 
 
65 (54.6%) 
206 
(60.8%) 
 
24 (48%) 
 
20 (20.8%) 
Employment status (n) 1391  74 160 65 111 226 47 99  119 339  51  100 
Employed, n (%) 413 (29.7%) 
 
18 (24.3%) 58 (36.3%) 17 (26.2%) 
33 
(29.7%) 
27 (12%) 20 (42.6%) 
37 
(37.4%) 
 
39 (32.8%) 
117 
(34.5%) 
 
25 (49%) 
 
22 (22%) 
Marital status (n) 1387  74 159 65 110 227 47 97  120 337  51  100 
Single, n (%) 242 (17.5%) 
 
8(10.8%) 36 (22.6%) 8 (12.3%) 
14 
(12.7%) 
26 
(11.5%) 
8 (17%) 
26 
(26.8%) 
 
19 (15.8%) 
60 
(17.8%) 
 
13 (25.5%) 
 
24 (24%) 
Married/cohabiting, n 
(%) 
955 (68.9%) 
 
56 (75.7%) 
103 
(64.8%) 
49 (75.4%) 
83 
(75.5%) 
158 
(69.6%) 
32 (68.1%) 
59 
(60.8%) 
 
82 (68.3%) 
234 
(69.4%) 
 
34 (66.7%) 
 
65 (65%) 
Table 3. Sociodemographic and clinical characteristics of the participating heart transplant recipients 
 
Overall 
N = 1397 
 
Europe n = 785 
 North America 
n = 461 
 Australia 
n = 51 
 South America 
n = 100 
 Belgium 
n = 74 
France 
n = 160 
Germany 
n = 67 
Italy 
n = 111 
Spain 
n = 227 
Switzerland 
n = 47 
UK 
n = 99 
 Canada 
n = 121 
USA 
n = 340 
 Australia 
n = 51 
 
Brazil n = 100 
Divorced/separated, n 
(%) 
149 (10.7%) 
 
8 (10.8%) 19 (12%) 6 (9.2%) 11 (10%) 
33 
(14.5%) 
6 (12.8%) 
10 
(10.3%) 
 
11 (9.2%) 30 (8.9%) 
 
4 (7.8%) 
 
11 (11%) 
Widowed, n (%) 41 (3%)  2 (2.7%) 1 (0.6%) 2 (3.1%) 2 (1.8%) 10 (4.4%) 1 (2.1%) 2 (2.1%)  8 (6.7%) 13 (3.9%)  0  0 
Time post‐HTx (n) 1395  74 160 67 111 227 47 99  121 340  49  100 
Years, Mean (SD) 3.4 (1.4)  3.4 (1.2) 3.6 (1.3) 3.4 (1.4) 3.2 (1.3) 3.6 (1.3) 3.5 (1.2) 3.5 (1.2)  3.7 (1.4) 3 (1.3)  4.2 (1.3)  2.8 (1.5) 
Heart failure etiology 
(n) 
1362 
 
74 159 65 111 226 47 93 
 
118 328 
 
48 
 
93 
Idiopathic 714 (52.4%) 
 
33 (44.6%) 88 (55.4%) 33 (50.8%) 
69 
(62.2%) 
130 
(57.5%) 
31 (66%) 
55 
(59.1%) 
 
68 (57.6%) 
144 
(43.9%) 
 
31 (64.6%) 
 
32 (34.4%) 
Ischemic 401 (29.4%) 
 
28 (37.8%) 44 (27.7%) 23 (35.4%) 
31 
(27.9%) 
64 
(28.3%) 
8 (17%) 
18 
(19.4%) 
 
35 (29.7%) 
128 
(39%) 
 
11 (22.9%) 
 
11 (11.8%) 
Valvular 44 (3.2%)  2 (2.7%) 10 (6.3%) 0 3 (2.7%) 15 (6.6%) 3 (6.4%) 1 (1.1%)  1 (0.9%) 4 (1.2%)  1 (2.1%)  4 (4.3%) 
Congenital 45 (3.3%) 
 
2 (2.7%) 5 (3.1%) 1 (1.5%) 3 (2.7%) 6 (2.7%) 2 (4.3%) 
14 
(15.1%) 
 
5 (4.2%) 4 (1.2%) 
 
2 (4.2%) 
 
1 (1.1%) 
Other 158 (11.6%) 
 
9 (12.2%) 12 (7.6%) 8 (12.3%) 5 (4.5%) 11 (4.9%) 3 (6.4%) 5 (5.4%) 
 
9 (7.7%) 
48 
(14.6%) 
 
3 (6.3%) 
 
45 (48.4%) 
                 
 
3.2 Overall prevalence of nonadherence to the nonpharmacologic treatment regimen 
Figure 1 shows the overall unadjusted and adjusted prevalence of nonadherence to the different 
nonpharmacologic treatment components. Based on the adjusted values, the highest prevalence of 
nonadherence was observed for physical activity: 47.8% (95% CI [45.2‐50.5]) of the sample were 
insufficiently physically active. Sun protection followed, with 39.9% (95% CI [37.3‐42.5]) not always 
protecting themselves as recommended. Of those who were advised to follow specific diets, 38.2% (95% 
CI [35.1‐41.3]) did not always or often follow recommendations. Heavy alcohol use was reported by 
22.9% (95% CI [20.8‐25.1]); 7.4% (95% CI [6.1‐8.7]) were still smokers or had stopped less than 1 year 
prior to data collection. Appointment keeping had the lowest nonadherence prevalence, with 5.7% (95% 
CI [4.6‐6.9]) missing at least one of their prior five outpatient clinic appointments.  
 
 
 
Figure 1 The adjusted and unadjusted overall prevalence of nonadherence to the nonpharmacologic treatment regimen  
3.3 Between‐country variability in nonadherence prevalence 
Figure 2 shows the between‐country variability in the prevalence of nonadherence to each of the 
investigated health behaviors. The largest variability (SD: 13.6%) was observed in heavy alcohol use, 
which ranged from 2% in Brazil to 42.9% in the UK. This was followed by variability in nonadherence to 
sun protection (SD: 9.5%): 24.1% of Spanish HTx recipients did not always use sun protection as 
opposed to 51.4% in Belgium, which had the highest prevalence. Variability in insufficient physical 
activity (SD: 8.5%) came third, with Spain's participants having the lowest rate (32%) and France's the 
highest (59.6%). Diet nonadherence came fourth (SD: 7.1%), varying from 26.6% (Spain) to 48.2% 
(USA). In Australia, no HTx recipients reported nonadherence to smoking cessation, while this number 
was 12.7% in France, with relatively low variability between countries (SD: 4%). Nonadherence to 
appointment keeping had the lowest variability (SD: 2.9%) ranging from 3% (UK) to 11.8% (Australia).  
 
  
 
 
 
Figure 2 Behavior‐wise investigation of the variability in nonadherence prevalence between countries  
Table 4 shows that the observed variability was statistically significant for all behaviors except 
appointment keeping. Figure 3 depicts each behavior's nonadherence prevalence per country, indicating 
which behaviors are least and most problematic within each country. 
Table 4. Chi‐square test results for the between‐country variability within each health behavior (showing nonadherence rates) 
 
Appointment keeping 
 
Smoking cessation 
 
Alcohol use 
 
Diet recommendations 
 
Sun protection 
 
Physical activity 
Adherent Not adherent 
 
Adherent Not adherent 
 
Adherent Not adherent 
 
Adherent Not adherent 
 
Adherent Not adherent 
 
Adherent Not adherent 
                  
Belgium 70 (94.6%) 4 (5.4%)  65 (87.8%) 9 (12.2%)  44 (59.5%) 30 (40.5%)  29 (60.4%) 19 (39.6%)  34 (48.6%) 36 (51.4%)  36 (48.6%) 38 (51.4%) 
France 150 (95.5%) 7 (4.5%)  137 (87.3%) 20 (12.7%)  96 (60%) 64 (40%)  75 (68.2%) 35 (31.8%)  92 (61.3%) 58 (38.7%)  59 (40.4%) 87 (59.6%) 
Germany 60 (92.3%) 5 (7.7%)  59 (92.2%) 5 (7.8%)  52 (77.6%) 15 (22.4%)  10 (52.6%) 9 (47.4%)  34 (54.8%) 28 (45.2%)  33 (50.8%) 32 (49.2%) 
Italy 107 (96.4%) 4 (3.6%)  108 (98.2%) 2 (1.8%)  99 (89.2%) 12 (10.8%)  45 (70.3%) 19 (29.7%)  83 (75.5%) 27 (24.5%)  53 (50.5%) 52 (49.5%) 
Spain 217 (96.9%) 7 (3.1%)  205 (92.8%) 16 (7.2%)  202 (89%) 25 (11%)  160 (73.4%) 58 (26.6%)  167 (75.9%) 53 (24.1%)  151 (68%) 71 (32%) 
Switzerland 43 (93.5%) 3 (6.5%)  45 (97.8%) 1 (2.2%)  32 (68.1%) 15 (31.9%)  10 (71.4%) 4 (28.6%)  23 (52.3%) 21 (47.7%)  30 (65.2%) 16 (34.8%) 
United Kingdom 96 (97%) 3 (3%)  94 (94.9%) 5 (5.1%)  56 (57.1%) 42 (42.9%)  18 (64.3%) 10 (35.7%)  49 (50%) 49 (50%)  63 (65.6%) 33 (34.4%) 
Canada 107 (92.2%) 9 (7.8%)  104 (90.4%) 11 (9.6%)  92 (76.7%) 28 (23.3%)  54 (61.4%) 34 (38.6%)  61 (52.6%) 55 (47.4%)  70 (60.3%) 46 (39.7%) 
USA 324 (96.4%) 12 (3.6%)  318 (94.9%) 17 (5.1%)  296 (87.3%) 43 (12.7%)  143 (51.4%) 135 (48.6%)  177 (53%) 157 (47%)  187 (56%) 147 (44%) 
Australia 45 (88.2%) 6 (11.8%)  51 (100%) 0 (0%)  33 (64.7%) 18 (35.3%)  16 (61.5%) 10 (38.5%)  32 (62.7%) 19 (37.3%)  28 (54.9%) 23 (45.1%) 
Brazil 87 (89.7%) 10 (10.3%)  93 (95.9%) 4 (4.1%)  98 (98%) 2 (2%)  40 (56.3%) 31 (43.7%)  64 (68.1%) 30 (31.9%)  39 (45.9%) 46 (54.1%) 
Chi‐square test 
results 
χ2(10, N = 1376) = 17.91, 
P = .056  
 χ2(10, N = 1369)  = 27.11, 
P = .003  
 χ2(10, N = 1394)  = 146.21, 
P < .001  
 χ2(10, N = 964)  = 31.22, 
P = .001  
 χ2(10, N = 1349)  = 56.24, 
P < .001  
 χ2(10, N = 1340)  = 40.67, 
P < .001  
            
 
 
 
 
 
 
Figure 3 Country‐wise investigation of nonadherence prevalence 
4 DISCUSSION 
This study is the largest ever to investigate the prevalence of nonadherence to various 
nonpharmacologic components of the post‐HTx regimen in the same sample. Its multinational setup 
allows examination of intercountry variability in nonadherence prevalence.  
 
The highest overall prevalence of nonadherence was noted for physical activity: 44.1% 
(observed/unadjusted rate)—more than double the prevalence in the general global adult population 
(23%).
17
 As insufficient activity is a major risk factor for several chronic diseases,
17
 including those that 
HTx recipients are at a higher risk of developing due to lifelong immunosuppressant intake, HTx 
recipients would benefit from interventions promoting physical activity. A meta‐analysis18 of 10 RCTs 
showed that cardiac rehabilitation programs could improve exercise capacity; however, most included 
studies focused on the immediate post‐transplant period and did not investigate the programs’ possible 
spin‐off effects, for example, higher physical activity levels in daily life. That is, physical activity is a 
poorly investigated domain in HTx.  
 
Next, 39.5% of our sample did not always apply sun protection when needed. As the prevalence of 
skin cancer in adult HTx recipients is 9.5% and 18.4% at 5 and 10 years post‐HTx,19 respectively, 
strategies that boost sun protection use may help to prevent skin cancer. Unfortunately, research on such 
interventions within transplantation is still in its infancy.  
 
The third highest nonadherence prevalence was for diet (37.8%). Poor dietary habits, for example, 
high caloric intake, can lead to overweight and obesity, which increase the burden of chronic illness in the 
general population
20
 (eg, diabetes and hypertension). Yet, the question of whether overweight and obesity 
negatively impact post‐HTx clinical outcomes also remains controversial. Most studies focusing on body 
mass index (BMI) at time of transplant have found an elevated risk for graft loss and mortality in HTx 
recipients with morbid obesity only (BMI > 35), but not in groups having a low BMI at transplantation.
21
 
Still, many patients gain weight post‐HTx: one prospective registry study22 reporting overweight and 
obesity in, respectively, 37% and 13.6% of patients at 3 years after HTx, which might ultimately elevate 
the risk for chronic disease. Unfortunately, few dietary interventions have been tested in transplant 
patients, leaving ample room for new evidence on how to effectively support healthy eating in HTx 
recipients.
23 
  
Fourth, heavy alcohol use was observed in 21.1% of the participants. One might argue that we used a 
very stringent definition; however, we followed CDC guidelines,
14
 which state that exceeding the 
specified limit increases the risk for over 200 diseases and injuries, including liver disease, cardiovascular 
disease, and some forms of cancer.
24
 Unfortunately, alcohol‐related research in transplantation focuses 
predominantly on liver transplant patients: the HTx literature is sparse. It remains unclear whether heavy 
alcohol use after HTx will affect graft or patient survival.  
 
Fifth, 6.6% of our sample smoked post‐transplant. While in line with previously reported numbers,7, 25 
this prevalence is presumably underestimated, bearing in mind that we used self‐report to document 
smoking.
26
 Given that post‐transplant smoking significantly reduces graft and patient survival,27,28 we 
recommend that HTx programs regularly assess patients’ smoking status via more objective means, for 
example, exhaled CO measurement, and should implement effective smoking cessation programs.
28
 
 
Finally, appointment nonadherence was observed in 5.1% of the sample, which is similar to 
previously reported numbers.
7,29
 Although the prevalence is relatively low, missing scheduled clinic visits 
after HTx is a risk factor for poor medication adherence, which elevates the risk for late acute rejections.
29
 
Therefore, transplant programs should do their best to reach out to HTx recipients who might miss or 
drop out of follow‐up care.  
 
In addition, we observed significant intercountry variability in nonadherence prevalence. The reasons 
behind this are open to speculation. For example, alcohol use at social occasions might be more common 
and acceptable in some countries. Likewise, patients might wrongfully assume that sun protection is less 
important in countries with cooler temperatures or fewer hours of sunshine. Summarizing the evidence on 
possible factors of nonadherence prevalence variability between countries for each studied behavior is 
beyond the scope of this paper. Based on these examples, however, it is clear that not only individual 
patient characteristics, but also factors related to the patients’ communities, healthcare providers, 
healthcare settings or policies, or cultural aspects might contribute to the observed differences. Therefore, 
future studies should use a multilevel approach to understand variability,
11
 incorporating all potentially 
relevant correlates of each relevant health behavior at the patient‐, micro‐, meso‐, and macro‐levels into a 
single model.  
4.1 Limitations and strengths of the study 
First, nonadherence was measured through self‐report. Given the multitude of variables collected in 
the main study, the large sample size, and the multinational nature of the study, this was unavoidable. 
Second, the cutoff points used to categorize patients as adherent/nonadherent were chosen based on 
criteria that might not be clinically meaningful for the HTx recipient population. This was necessary in 
the absence of recommendations regarding appropriate levels of the investigated health behaviors for HTx 
recipients. Third, HTx recipients were recruited and data collected during follow‐up clinic visits. This 
might have skewed certain results, for example, regarding appointment nonadherence, due to the 
possibility of including more adherent participants. Fourth, centers participated on a voluntary basis and 
could only participate if they performed at least 10 procedures, on average, per year. Smaller centers 
might organize follow‐up care differently or might lack the experience or resources to monitor adherence 
or lifestyle factors, possibly resulting in higher nonadherence rates than those documented in the present 
paper. Finally, the design of the study was cross‐sectional, giving a static rather than a dynamic picture of 
nonadherence over time.
30 
 
Strengths include our large multinational sample. Moreover, studying all nonpharmacologic 
components of the post‐transplant regimen in the same patients is unique and allows a clear understanding 
of the corresponding adherence issues in HTx recipients. The use of random sampling at the patient level, 
applying the same nonadherence measures and operational definitions and our adjustment of prevalence 
rates to ensure appropriate representativeness of each country in relation to the entire sample (based on its 
HTx recipient population) further strengthens our belief that the numbers presented in this paper 
accurately depict the magnitude of the problem.  
 
To summarize, HTx recipients’ nonadherence to the nonpharmacologic components of the treatment 
regimen appears to be a major problem. By displaying the prevalence by behavior as well as by country, 
we hope our results will help clinicians prioritize their needs regarding tailored adherence‐enhancing 
interventions.   
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